Mind Medicine (MindMed) Inc. (MNMD)
Market Cap | 706.92M |
Revenue (ttm) | n/a |
Net Income (ttm) | -95.73M |
Shares Out | 41.33M |
EPS (ttm) | -2.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,153,860 |
Open | 9.50 |
Previous Close | 9.50 |
Day's Range | 9.26 - 10.00 |
52-Week Range | 2.41 - 11.10 |
Beta | 2.46 |
Analysts | Strong Buy |
Price Target | 30.50 (+224.47%) |
Earnings Date | May 2, 2024 |
About MNMD
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the tr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price forecast is $30.5, which is an increase of 224.47% from the latest price.
News
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
PLTR, MNMD, ODD: Finding Value in the Market
Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and ...
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral...
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product ...
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product...
MindMed Reports 2023 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product c...
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product c...
MindMed Announces Business Update and Anticipated Milestones for 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to tre...
Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this year
A financial backer of an effort to legalize the drug MDMA for therapeutic use sees the potential for “exponential growth” should it win approval from the U.S. Food and Drug Administration, possibly ov...
MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder
Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores b...
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candida...
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended September 30, 2023.
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will present preclinical data for MM-402 in a model for autism spectrum disorder.
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will participate in a panel at the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit.
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has completed enrollment and dosing in Study MMED008, the Phase 2b study evaluating MM-120 (lysergide D-tartrate) for the treatment of GAD.
MindMed to Participate at September Investor Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--The MindMed management team will participate in two September investor conferences.
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended June 30, 2023.
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed has entered into a license agreement to access Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology.
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed will provide a corporate update and review the Company's results for the quarter ended June 30, 2023.
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
NEW YORK--(BUSINESS WIRE)---- $MNMD--Members of MindMed's management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on Monday, June 26.